Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Lexiscan® (Regadenoson) Injection Study in Subjects With Asthma or Chronic Obstructive Pulmonary Disease (COPD) Presented as Late-Breaker at American Society of Nuclear Cardi…

September 25, 2010 By Bio-Medicine.Org

PHILADELPHIA, Sept. 25 /PRNewswire/ — Today Astellas Pharma US,
Inc. (“Astellas”) announced results of a Phase IV study showing
Lexiscan® (regadenoson) Injection was comparable to placebo in
causing a >15% decrease in forced expiratory volume in one
second (FEV1) in subjects with asthma or chronic obstructive
pulmonary disease (COPD) who are likely candidates for myocardial
perfusion imaging (MPI) studies(1). Results were presented during
an oral presentation today at the 15th Annual Scientific Sessions
of the American Society of Nuclear Cardiology (ASNC) in
Philadelphia, Pennsylvania during a session highlighting
late-breaker data.

Statistically, regadenoson was found to be not significantly
different from placebo in causing a >15% decrease in FEV1 in
patients with asthma (p = 0.1451) or COPD (p = 0.5790).
Additionally, the change in FEV1 was not affected by baseline
disease severity for either the asthma or the COPD subject
groups.

Researchers evaluated 999 adult male and female patients (532
asthma and 467 COPD) 18 years of age and older in a multicenter,
randomized, double-blind, placebo-controlled study to determine the
safety and tolerability of regadenoson in subjects with asthma
(FEV1 >60% predicted) or stable COPD (FEV1/FVC <0.70).
The subjects had a diagnosis of CAD or risk factors for CAD as
determined by a current medical diagnosis of at least two of the
following conditions: Type 2 diabetes, hypertension,
hypercholesterolemia, current or history of cigarette smoking
(minimum 10 pack-years exposure) or obesity Body Mass Index (BMI
> 30). A 2:1 randomization to receive a single 10-second IV
injection of Lexiscan 0.4 mg (in 5 mL) or placebo was used.

Treatment-emergent adverse events were similar in frequency and
severity to those observed in previous studies of regadenoson. Two
regadenoson subjects in the COPD group received aminophylline for
treatment of adverse events.

About Myocardial Perfus

‘/>”/>

SOURCE

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 20, 2022
DeviceTalks Boston Post-Game – Editors’ Top Moments, Insulet’s Eric Benjamin on future of Omnipod 5
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech